35 results about "Hematopoietic growth factor" patented technology

The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

The invention provides a method for obtaining a hemopoietic stem cell by using a three-dimensional induction system. A three-dimensional cell culture medium or cell culture bracket, such as a three-dimensional cell culture system made of the materials such as hydrogel, seaweed and the like is utilized, and / or combined with matrix cells such as bone marrow cell, mouse bone marrow cell lines OP9, OP9DL1 and the like, and / or combined with a plurality of factors including mesoderm induction factors, hematopoietic growth factor and the like to induce multipotent stem cells to differentiate into hemopoietic stem cells. A new method for obtaining the hemopoietic stem cells is built. The system for efficiently inducing the multipotent stem cells to differentiate into the hemopoietic stem cells by using a three-dimensional induction system and / or combining with matrix cells such as bone marrow cell and the like and / or a plurality of factors is built for the first time. Theoretical basis and a technology platform are provided for obtaining clinically available hemopoietic stem cells, and a new method and a new concept are developed for application of hematopoietic cells derived from multipotent stem cells in the fields such as disease mechanism exploration, drug screening and the like.

A serum-free culture medium for hematopoietic stem cell (HSC) expansion is provided. The serum-free culture medium includes a serum-free base medium, cytokines, an umbilical cord mesenchymal stem cell conditioned medium and supplemental components. The cytokines comprise stem cell factor, thrombopoietin and hematopoietic growth factor Flt3 ligand. The umbilical cord mesenchymal stern cell conditioned medium is derived from culturing human umbilical cord mesenchymal stem cells. The supplemental components comprise vitamin C, vitamin E or a combination of vitamin C and vitamin E.

The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

The present invention discloses the cloning of a new cDNA, HGFIN, from stimulated bone marrow stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The novel gene, HGFIN, encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. HGFIN is implicated in the treatment of hyperproliferative disorders, particularly bone and breast cancer, because it acts to suppress the proliferating cells.

Bone marrow (BM) is the major organ where immune cells are derived. Homeostasis in the BM is maintained by inter- and intra-cellular interactions by the various subsets of BM cells. The present invention discloses the cloning of a new cDNA from stimulated BM stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The cloned cDNA was designated ‘Hematopoietic Growth Factor Inducible Neurokinin-1 type’ (HGFIN) gene based on its expression in differentiated hematopoietic cells. Hence, the present invention provides a novel gene, HGFIN, which encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. The protein of the present invention may be involved as a central mediator of white blood cell, progenitor, differentiation, and therefore, may be useful in the prevention and treatment of lymphoproliferative syndromes such as B-cell related maladies, including but not limited to acute and chronic myeloid and lymphocytic leukemia as well as the B-cell subtype of Hodgkin's and non-Hodgkin's lymphomas.

The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

The invention provides a culture system for hematopoietic stem cell amplification. The culture system comprises a basal culture medium and a composition for promoting hematopoietic stem cell amplification, and the composition contains early hematopoietic growth factors related to hematopoietic regulation. The invention further provides a method adopting the culture system for in-vitro amplification of hematopoietic stem cells and a kit comprising the composition for promoting hematopoietic stem cell amplification. By adopting the culture system for in-vitro amplification of the hematopoietic stem cells, the hematopoietic stem cells can be amplified by more than hundreds of times, so that the problem of hematopoietic stem cell insufficiency in the process of treating blood system diseases can be solved effectively.

A hematopoietic growth factor delivery composition includes a hematopoietic growth factor, a liquid vehicle, a first biocompatible polymer and a second biocompatible polymer. The composition exhibits reverse-thermal viscosity behavior, due to interaction between the first biocompatible polymer and the liquid vehicle. The second biocompatible polymer helps to protect the first biocompatible polymer from being dissolved in vivo following administration to a host.

The invention pertains to methods and devices for the in vitro culture of hematopoietic progenitor cells in the absence of exogenously added hematopoietic growth factors. The hematopoietic progenitor cells are cultured in the absence of exogenously added hematopoietic growth factors without loss in cell progenitor cell numbers and / or functionality, while maintaining progenitor cell pluripotency.

The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

A screening method for identifying mutant polypeptides having at least one amino acid difference from a wild type protein involved in a receptor-ligand interaction is disclosed. Also disclosed are mutant polypeptides of the hematopoietic growth factor flt3-Ligand (flt3-L) identified using this method, nucleic acids encoding these flt3-L mutant polypeptides, and methods of treatment involving in vitro and in vivo use of the mutant polypeptides and nucleic acids.

The invention pertains to methods and devices for the long term, in vitroculture of hematopoietic progenitor cells in the absence of exogenously added hematopoietic growth factors, improved methods for the introduction of foreign genetic material into cells of hematopoietic origin, and to apparatus for performing these methods. The hematopoietic progenitor cells are cultured on a three-dimensional porous biomaterial. The three-dimensional porous biomaterial enhances hematopoietic progenitor cell survival and leads to an expansion of progenitor cell numbers and / or functionality, while maintaining progenitor cell pluripotency in the absence of exogenous growth factors. In addition, the three-dimensional porous biomaterial supports high level transduction on cells cultured upon such environment.

The invention relates to a method of acquiring hematopoietic stem cells (HSCs) by means of three dimensional inducing system with high efficiency—which makes use of three-dimensional cell culture matrix or cell culture scaffolds, such as three-dimensional cell culture system which is made from hydrogel, seaweed and other materials, and / or associating stromal-cell including bone marrow cell, mouse bone marrow cell line OP9, OP9DL1 and so on, and / or associating multiple factors including mesoderm inducible factor, hematopoietic growth factor etc which can induce pluripotent stem cells to differentiate into hematopoietic stem cells. The invention sets up a new method of acquiring hemopoietic stem cells, establishing a system that induces pluripotent stem cells to differentiate into hemopoietic stem cells with high efficiency by means of utilizing dimensional inducing system and / or associating stromal-cell including bone marrow cell and / or multiple factors for the first time, which provide a theoretical basis and technology platform for acquiring clinical available hematopoietic stem cells, and expand additional methodologies and ideas in fields of disease mechanism exploring, drug screening etc for hematopoietic cells from pluripotent stem cells.

The invention pertains to methods and devices for the long term, in vitroculture of hematopoietic progenitor cells in the absence of exogenously added hematopoietic growth factors, improved methods for the introduction of foreign genetic material into cells of hematopoietic origin, and to apparatus for performing these methods. The hematopoietic progenitor cells are cultured on a three-dimensional porous biomaterial. The three-dimensional porous biomaterial enhances hematopoietic progenitor cell survival and leads to an expansion of progenitor cell numbers and / or functionality, while maintaining progenitor cell pluripotency in the absence of exogenous growth factors. In addition, the three-dimensional porous biomaterial supports high level transduction on cells cultured upon such environment.

The present invention is directed to new methods for treating a subject in need of hematopoietic stimulation. The present invention is also directed to new methods of neutrophil stimulation in a subject in need thereof. The present invention is also directed to new methods of platelet stimulation in a subject in need thereof. The methods comprise administering to the subject an effective amount of a peptide optionally in combination of a hematopoietic growth factor, wherein the peptide is:(i) Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Xaa-Leu-Gln-Asp-Val-NH2 (SEQ ID NO: 1), where Xaa=Lys, Leu, Ile, Nle or Met, preferably Xaa=Lys; or(ii) Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Xaa-Leu-Gln-Asp-Val-Y (SEQ ID NO: 2), cyclized in the form of a lactam between Glu22 and Lys26,Xaa=Leu, Ile, Nle or Met,Y=NH2 or OH.Preferably, Xaa is Leu and Y is NH2.

Methods and compositions comprising hematopoietic growth factor proteins and / or protein analogs thereof and / or combinations thereof and angiotensin converting enzyme inhibitors to treat the acute and long term adverse effects of radiation exposure in subjects who have been or will be exposed to radiation are disclosed.

The invention provides a serum-free medium and a method for amplifying hematopoietic stem cells. The serum-free culture medium comprises a serum-free basal culture medium, cytohormone, an umbilical cord mesenchymal stem cell conditioned culture medium and auxiliary components. The cytohormone comprises a stem cell factor, thrombopoietin and a hematopoietic growth factor Flt3 ligand. The umbilicalcord mesenchymal stem cell conditioned medium is derived from cultured human umbilical cord mesenchymal stem cells. The auxiliary components comprise vitamin C, vitamin E or a combination of vitamin Cand vitamin E.

The invention relates to a series of peptides capable of promoting the propagation of marrow karyocyte and marrow stroma cell, and its application, its biological activity is superior to the existing hematopoiesis growth factors, and has the advantages of simplified production process and stabilized effect. The medicament can be used for effectively treating panhematopenia for patients with regenerative anemia and cancer.

Embodiments of the present disclosure concern improvements to cell therapy for cancer. In certain embodiments, an immune cell lacks expression of hematopoietic growth factor receptor c-MPL (myeloproliferative leukemia), the receptor for thrombopoietin (TPO), and supplementation of this effect allows an improvement for cancer cell therapy, including of hematological malignancies. In specific embodiments, immune cells comprise recombinant c-MPL expression or parts thereof and the cells have enhanced co-stimulation and cytokine signals and improved activation, persistence, and anti-tumor function compared to cells that lack recombinant c-MPL expression.

The present invention discloses the cloning of a new cDNA, HGFIN, from stimulated bone marrow stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The novel gene, HGFIN, encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. HGFIN is implicated in the treatment of hyperproliferative disorders, particularly bone and breast cancer, because it acts to suppress the proliferating cells.

The invention relates to the combined use of selective serotonin reuptake inhibitors (SSRIs) and hematopoietic growth factors as a drug and particularly for treating cytopenia related to hematopoietic diseases or chemotherapy, and also to a pharmaceutical kit comprising both SSRIs and hematopoietic growth factors. This combination is more particularly used for treating patients presenting cytopenia, and patients in need of chemotherapy and more particularly to reduce length of chemotherapy-induced aplasia.

The present disclosure provides methods of treating neuroblastoma using an anti-GD2 antibody, at least one chemotherapeutic agent, and at least one hematopoietic growth factor. The present disclosure also provides compositions for treating neuroblastoma.

The invention relates to a traditional Chinese medicine preparation for treating leucopenia after chemotherapy. The traditional Chinese medicine preparation comprises radix pseudostellariae, codonopsis pilosula, angelica sinensis, glossy privet fruit, herba epimedii, fructus amomi, endothelium corneum gigeriae galli, rhizoma gastrodiae, jujube kernel, tuber fleeceflower stem, orange peel, herba pyrrosiae, caulis spatholobi, tortoise plastron, Chinese yam and polygala tenuifolia. The traditional Chinese medicine preparation has the effects of tonifying the spleen and kidneys, reinforcing qi, nourishing blood, regulating and nourishing qi and blood and nourishing yin to lessen fire, is capable of improving the immunity, controlling the infection, restraining the hypersplenism, improving the hematopoietic growth factors, maintaining the medullary hematopoiesis function, increasing the quantity of hemameba, restoring the hemopoietic system, increasing the neutrophile granulocyte, strengthening the phagocytosis sterilization and chemotaxis functions of the neutrophile granulocyte and promoting the relative decrease of the lymphocyte percentage after being taken, and is capable of thoroughly relieving the symptoms of headache, low-grade fever, lacking in strength, general malaise and pharyngeal infection caused by leucopenia after chemotherapy and regulating the endocrine disorder through comprehensive treatment so as to finally realize the aim of thoroughly curing the leucopenia after chemotherapy.

The invention discloses application of ROS (reactive oxygen species) response type nanoparticles coated with hematopoietic growth factors in preparation of drugs for treating hematopoietic injury. Experiments prove that the bioavailability of the ROS response type nanoparticles coated with hematopoietic growth factors is improved, and the nanoparticles can be rapidly taken by cells to play a role. The nanoparticles deliver cytokines, can remove ROS (reactive oxygen species) generated by radiation, and can continuously release the cytokines to promote hematopoiesis. The hematopoietic microenvironment is improved, and the nanoparticles and the hematopoietic factor act at the same time to treat the hematopoietic injury after radiation. Meanwhile, animal experiment level proves that the nanoparticles have better disease treatment effect compared with free drugs, and the synergistic effect of the nanoparticles is shown.

The present disclosure provides methods of treating neuroblastoma using an anti-GD2 antibody, at least one chemotherapeutic agent, and at least one hematopoietic growth factor. The present disclosure also provides compositions for treating neuroblastoma.